12 HR Carbamazepine 200 MG Extended Release Oral Tablet

INDICATIONS AND USAGE Epilepsy Carbamazepine extended-release tablets are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine extended-release tablets as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine extended-release tablets (see PRECAUTIONS, General ). Trigeminal Neuralgia Carbamazepine extended-release tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Zydus Pharmaceuticals (USA) Inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] dyspnoea` `[3] toxicity to various agents` `[4] off label use` `[5] gynaecomastia` `[6] fatigue` `[7] completed suicide` `[8] nausea` `[9] drug abuse` `[10] drug interaction`

5 years ago

ROUND WHITE 556

HOW SUPPLIED

CARBAMAZEPINE Extended-release Tablets, USP 100 mg are white to off white colored, round shaped, beveled edge, biconvex, coated tablets with release portal on one side and imprinted with '555' with black ink on any one side of the tablet and are supplied as follows: NDC 68382-555-06 in bottles of 30 tablets NDC 68382-555-16 in bottles of 90 tablets NDC 68382-555-01 in bottles of 100 tablets NDC 68382-555-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets

CARBAMAZEPINE Extended-release Tablets, USP 200 mg are white to off white colored, round shaped, beveled edge, biconvex, coated tablets with release portal on one side and imprinted with '556' with black ink on any one side of the tablet and are supplied as follows: NDC 68382-556-06 in bottles of 30 tablets NDC 68382-556-16 in bottles of 90 tablets NDC 68382-556-01 in bottles of 100 tablets NDC 68382-556-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets

CARBAMAZEPINE Extended-release Tablets, USP 400 mg are white to off white colored, round shaped, beveled edge, biconvex, coated tablets with release portal on one side and imprinted with '557' with black ink on any one side of the tablet and are supplied as follows: NDC 68382-557-06 in bottles of 30 tablets NDC 68382-557-16 in bottles of 90 tablets NDC 68382-557-01 in bottles of 100 tablets NDC 68382-557-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets Storage Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature] . Protect from moisture. Dispense in a tight container (USP). *Trademarks are the property of their respective owners. Medication Guide available at www.zydususa.com/medguides or call 1-877-993-8779. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals ( USA) Inc. Pennington, NJ 08534 Rev.: 02/24

More pills like ROUND 556

Related Pills

12 HR Carbamazepine 400 MG Extended Release Oral Tablet

Zydus Pharmaceuticals (USA) Inc.

12 HR Carbamazepine 100 MG Extended Release Oral Tablet

Zydus Pharmaceuticals (USA) Inc.

temazepam capsule

amneal pharmaceuticals llc

Propranolol Hydrochloride 40 MG Oral Tablet

Actavis Pharma, Inc.

Propranolol Hydrochloride 40 MG Oral Tablet

Actavis Pharma, Inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site